Methods for treating aging-related disorders

By administering NK cell activator or activating NK cells to subjects suffering from senile diseases, the senile and related diseases caused by the accumulation of senescent cells is solved, and the effects of improving the texture of the skin and hair, reducing blood sugar and reducing obesity are achieved.

CN112888445BActive Publication Date: 2025-06-10IMMUNITYBIO INC
View PDF 66 Cites 0 Cited by

Patent Information

Application Number
CN201980070232.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-07-31
Filing Date
2019-08-30
Publication Date
2025-06-10
Estimated Expiration
2039-08-30

AI Technical Summary

Technical Problem

The prior art is difficult to effectively solve the accumulation of senescent cells in senile-related diseases and conditions, resulting in the aggravation of senile and related diseases.

Method used

Treat senile-related problems such as obesity by administering natural killer (NK) cell activator or activating NK cells to subjects suffering from senile-related diseases to reduce or kill senescent cells, thereby improving the texture and appearance of the skin and hair.

Benefits of technology

Effectively reduce the number of senescent cells, improve the texture of the skin and hair, reduce blood sugar levels, and reduce the symptoms of senile related diseases such as obesity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN112888445B_ABST
    Figure CN112888445B_ABST
Patent Text Reader

Abstract

The present invention provides methods for treating aging-related diseases or conditions in a subject in need thereof, killing or reducing the number of senescent cells in a subject in need thereof, improving the texture and / or appearance of the skin and / or hair of a subject in need thereof, and contributing to the treatment of obesity in a subject in need thereof, the methods comprising administering a therapeutically effective amount of one or more natural killer (NK) cell activators and / or a therapeutically effective number of activated NK cells to the subject.
Need to check novelty before this filing date? Find Prior Art

Claims

1. Use of a multi-chain chimeric polypeptide in the preparation of a medicament for treating pancreatic cancer or melanoma in a subject, wherein, the multi-chain chimeric polypeptide comprises: (a) a first chimeric polypeptide comprising: (i) a first target-binding domain; (ii) a soluble tissue factor domain; and (iii) a first domain of an affinity domain pair; and (b) a second chimeric polypeptide comprising: (i) a second domain of the affinity domain pair; and (ii) a second target-binding domain, wherein the first chimeric polypeptide consists of SEQ ID NO: 236 and the second chimeric polypeptide consists of SEQ ID NO: 193, and wherein the first chimeric polypeptide and the second chimeric polypeptide associate through the binding of the first domain and the second domain of the affinity domain pair.

2. The use according to claim 1, wherein the multi-chain chimeric polypeptide causes a reduction in the activation of the TGF-β receptor.

Citation Information

Patent Citations

  • Human monoclonal antibodies against TGF-beta ii receptor and medicinal use thereof

    EP1245676A1

  • Portable protecting apparatus.

    US1122016A

  • Treating immunological disorders using agonists of interleukin-21 / interleukin-21 receptor

    US20060159655A1

  • Methods of modulating a mammalian cytokine

    US20070160579A1

  • Binding members for interleukin-4 receptor alpha (IL-4Ra) - 173

    US20120171197A1